Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

First-generation bromodomain extra-terminal protein (BETP) inhibitors (BETi) (e.g., OTX015) that disrupt binding of BETP BRD4 to chromatin transcriptionally attenuate AML-relevant progrowth and prosurvival oncoproteins. BETi treatment induces apoptosis of AML BPCs, reduces in vivo AML burden and ind...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Cancer J
Autors principals: Fiskus, Warren, Cai, Tianyu, DiNardo, Courtney D., Kornblau, Steven M., Borthakur, Gautam, Kadia, Tapan M., Pemmaraju, Naveen, Bose, Prithviraj, Masarova, Lucia, Rajapakshe, Kimal, Perera, Dimuthu, Coarfa, Cristian, Mill, Christopher P., Saenz, Dyana T., Saenz, David N., Sun, Baohua, Khoury, Joseph D., Shen, Yu, Konopleva, Marina, Bhalla, Kapil N.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6333829/
https://ncbi.nlm.nih.gov/pubmed/30647404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0165-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars